cmet/hgfr

Amivantamab (Anti-c-Met) is a human antibody that recognizes the MET proto-oncogene (MET) and can be used in cancer-related research.

Telisotuzumab(ABT-700) is a humanized recombinant antibody targeting the therapeutic hepatocyte growth factor receptor (MET) with high affinity for c-Met.Telisotuzumab has inhibitory effects on c-Met signaling and antitumor activity.

Emibetuzumab is a potent humanized bivalent MET antibody (IgG4 type). Emibetuzumab has antitumor activity, inhibition of HGF-dependent and independent MET pathway activation and tumor growth, and can be used to study advanced castration-resistant prostate cancer.

Rilotumumab (AMG 102) is a monoclonal antibody targeting hepatocyte growth factor that inhibits HGF/ MET-driven signaling. Rilotumumab has antitumor effects and can be used to study castration-resistant prostate cancer (CRPC) and gastric cancer.

Onartuzumab (MetMAb) is a humanized anti-tyrosine kinase c-MET monovalent monoclonal antibody.Onartuzumab has antitumor activity with inhibitory effects on HGF binding, receptor phosphorylation, and signal transduction.

Davutamig (REGN-5093) is a humanized IgG4-kappa anti-MET monoclonal antibody that targets two distinct, nonoverlapping epitopes on the MET receptor and functions as an antineoplastic agent [1].

Ficlatuzumab is a humanized monoclonal antibody that specifically targets and neutralizes the biological activity of human hepatocyte growth factor (HGF), by inhibiting HGF, Ficlatuzumab effectively blocks c-Met receptor-mediated downstream signaling pathways responsible for cancer cell proliferation, migration, and invasion, demonstrating applicable use for the treatment of squamous cell carcinoma.

Bafisontamab (EMB-01) is a bispecific antibody targeting EGFR and cMET, exhibiting antitumor activity [1].

Narnatumab (IMC-RON8) is a humanized antibody targeting the macrophage-stimulating receptor (RON) with antitumor activity, used in advanced malignant solid tumors research.

Telisotuzumab vedotin (ABBV-399) is an ADC compound targeting c-Met with antitumor activity, used for research in recurrent squamous cell lung cancer.

ABBV-303 is a multispecific NK cell antibody utilizing TriNKET technology to target c-Met for NK cell redirection therapy. It comprises three functional components: a single-chain variable fragment (scFV) targeting c-Met, a Fab arm engaging NKG2D, and an Fc fragment directed at NK cell CD16a [1].

SAIT-301 is a humanized antibody expressed in CHO cells, targeting HGFR/c-Met. It consists of a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For the isotype control of SAIT-301, refer to HumanIgG1kappa, Isotype Control.

Anti-MSPR/RON/CD136 Antibody (H5B14) is a human-sourced antibody expressed in CHO cells, targeting MSPR/RON/CD136. It features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 156.7 kDa. For an isotype control, refer to HumanIgG1kappa, Isotype Control.

Amivantamab (JNJ-61186372) is a humanized antibody that recognizes epidermal growth factor receptor (EGFR) and MET proto-oncogene (MET), with anticancer and anti-tumor activities, preventing ligand binding to EGFR and MET and receptor dimerization that inhibits downstream signal transduction. Amivantamab can induce Fc-dependent endocytosis of macrophages and antibody-dependent cytotoxicity of natural killer cells, and can be used to study metastatic non-small cell lung cancer.

Telisotuzumab Adizutecan (ABBV-400) is an antibody-drug conjugate (ADC) targeting c-Met. It consists of the humanized anti-c-Met antibody Telisotuzumab, a stable cleavable linker (TGA-Val-Ala-NH2-bicyclo[1.1.1]pentane), and a topoisomerase 1 inhibitor (7-MAD-MDCPT). The drug-linker conjugate of the ADC is TGA-Val-Ala-NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT. Telisotuzumab Adizutecan exhibits significant antitumor activity against advanced solid tumors such as colorectal, gastric, and non-small cell lung cancers.

SFN68 is a humanized IgG1 neutralizing monoclonal antibody targeting HGF. It significantly inhibits the interaction between HGF and c-Met, the activation of c-Met, and HGF-mediated cell scattering and proliferation. SFN68 is applicable for cancer research.

CE-355621 is a humanized anti-c-Met IgG1 monoclonal antibody. It effectively binds to human c-Met in A549 cells (KD= 200 pM, IC50= 466 pM) and also binds effectively to c-Met in cynomolgus monkey kidney cells (KD= 610 pM). CE-355621 inhibits the c-Met signaling pathway by blocking HGF binding and significantly suppresses tumor growth dependent on the c-Met/HGF pathway. It is applicable for research in cancers such as glioblastoma and gastric cancer.

ARGX-111 is a defucosylated anti-MET antibody that inhibits both HGF-dependent and HGF-independent signaling and reduces MET expression on tumor cell surfaces. It suppresses tumor metastasis by enhancing antibody-dependent cellular cytotoxicity (ADCC) to deplete MET-expressing circulating tumor cells. In metastatic breast cancer orthotopic mouse models, ARGX-111 has been shown to deplete circulating tumor cells and inhibit bone and lung metastases. This compound is suitable for research in cancers such as breast cancer.

Umikibart is a humanized IgG4κ antibody targeting HGF, with the corresponding isotype control being HumanIgG4(S228P) kappa, Isotype Control.

Anti-HGF Antibody (7V7) is a mouse (varialbe region) / human (kappa / IgG1 constant) chimeric monoclonal antibody targeting Human HGF.

REGN5093-M114 is a bispecific antibody-drug conjugate (ADC) that targets two epitopes of the MET receptor tyrosine kinase, effectively inhibiting NSCLC cell proliferation and demonstrating antitumor activity in mouse models. REGN5093-M114 is composed of the human monoclonal anti-MET antibody Davutamig and a tubulin-inhibiting linker-payload.

Anti-MST1R Antibody (MOR07692) is a humanized IgG1 monoclonal antibody specifically targeting MST1R.

Anti-c-Met/HGFR Antibody is a humanized IgG1 monoclonal antibody that targets c-Met.